Template to improve glycemic control without reducing adiposity or dietary fat


Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana

Submitted 27 December 2010; accepted in final form 21 January 2011

Krishnapuram R, Dhurandhar EJ, Dubuisson O, Kirk-Ballard H, Bajpeyi S, Butte N, Sothern MS, Larsen-Meyer E, Chalew S, Bennett B, Gupta AK, Greenway FL, Johnson W, Brashear M, Reinhart G, Rankinen T, Bouchard C, Cefalu WT, Ye J, Ravier R, Zuberi A, Dhurandhar NV. Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab 300: E779–E789, 2011. First published January 25, 2011; doi:10.1152/ajpendo.00703.2010.—Drugs that improve chronic hyperglycemia independently of insulin signaling or reduction of adiposity or dietary fat intake may be highly desirable. Ad36, a human adenovirus, promotes glucose uptake in vitro independently of adiposity or proximal insulin signaling. We tested the ability of Ad36 to improve glycemic control in vivo and determined if the natural Ad36 infection in humans is associated with better glycemic control. C57BL/6J mice fed a chow diet or made diabetic with a high-fat (HF) diet were mock infected or infected with Ad36 or adenovirus Ad2 as a control for infection. Postinfection (pi), systemic glycemic control, hepatic lipid content, and cell signaling in tissues pertinent to glucose metabolism were determined. Next, sera of 1,507 adults and children were screened for Ad36 antibodies as an indicator of past natural infection. In chow-fed mice, Ad36 significantly improved glycemic control for 12 wk pi. In HF-fed mice, Ad36 improved glycemic control and hepatic steatosis up to 20 wk pi. In adipose tissue (AT), skeletal muscle (SM), and liver, Ad36 upregulated distal insulin signaling without recruiting the proximal insulin signaling. Cell signaling suggested that Ad36 increases AT and SM glucose uptake and reduces hepatic glucose release. In humans, Ad36 infection predicted better glycemic control and lower hepatic lipid content independently of age, sex, or adiposity. We conclude that Ad36 offers a novel tool to understand the pathways to improve hyperglycemia and hepatic steatosis independently of proximal insulin signaling, and despite a HF diet. This metabolic engineering by Ad36 appears relevant to humans for developing more practical and effective antidiabetic approaches.

Impaired glycemic control is associated with serious health conditions, including diabetes and cardiovascular risks (23). Lifestyle changes to reduce dietary fat intake and obesity can substantially ameliorate the impairment or further deterioration of glycemic control (61). Unfortunately, despite their obvious health benefits, compliance with lifestyle changes to achieve sustained improvements in diet or obesity has proved challenging for the general population. Hence, drugs often play an important role in controlling hyperglycemia. Particularly, antidiabetic agents that improve chronic hyperglycemia, independent of reduction of adiposity or dietary fat intake would be extremely attractive and of practical benefit.

Most of the currently available antihyperglycemic agents target the insulin signaling pathway, which could be broadly divided into proximal signaling [binding of insulin to its receptor (IR)], followed by the activation of insulin receptor substrate (IRS)-1 and IRS-2, and distal signaling, which includes the activation of phosphatidylinositol 3-kinase (PI3K) pathway by IRS-1 and IRS-2 and which via the activation of Akt2 leads to glucose transporter-mediated glucose disposal. However, in diabetes, proximal insulin signaling is often impaired (45, 53), which could render a proximal insulin signaling-based agent less effective. Therefore, drugs that improve hyperglycemia through a mechanism that is independent of insulin signaling, or at least independent of proximal insulin signaling, may be more effective. Interestingly, studies of human adenovirus Ad36 offer a new model to develop therapeutic approaches to enhance glycemic control despite adiposity and high-fat intake and independently of proximal insulin signaling.

Ad36 was first isolated from a human fecal sample (63). It is among 51 human adenovirus serotypes (63), which are associated with infections of the respiratory and gastrointestinal tracts. Experimental Ad36 infection of chickens, mice, rats, and nonhuman primates increases adiposity in chow-fed animals (14, 15, 43, 47) yet improves systemic glycemic control (43). In vitro, Ad36 downregulates IR and IRS-1 activation yet robustly upregulates the distal insulin signaling via a Ras- and PI3K-dependent mechanism, leading to up regulation of glucose transporters and, consequentially, enhanced glucose uptake (49, 62). These findings have potentially valuable applications. Ad36 may offer a novel tool to reveal how to manipulate host metabolism to improve glycemic control in the presence of excess adiposity and without recruiting proximal insulin signaling.

To accomplish this, we first tested whether Ad36 would improve glycemic control in vivo in a mouse model. Furthermore, to evaluate the human relevance of the metabolic effects of Ad36, we determined whether in humans natural Ad36 infection is associated with better glycemic control, adjusted for age, sex, and adiposity. Considering the close association of glycemic control with hepatic steatosis (HS), we also determined the effect of Ad36 on hepatic lipid accumulation in mice and humans, as described below.

METHODS

Animal Experiments

The Institutional Animal Care and Use Committee (IACUC) of the Pennington Biomedical Research Center approved the protocols for animal studies. Mice were purchased from The Jackson Laboratories (Bar Harbor, ME) and placed on a 12:12-h light-dark cycle at 25°C.
Ad36 attenuates diet-induced hyperglycemia

Techniques and Assays

Additional details about the techniques and assays are described in supplementary information.

Viruses. Ad36 and Ad2 were obtained from American Type Culture collection (ATCC cat. nos. VR913 and VR846, respectively). Ad36 was plaque purified and propagated in A549 cells (human lung cancer cell line) as described (13, 14).

Biochemical assays. Glucose was measured using the Raichem glucose Oxidase method (R80038), and insulin was measured with an ultrasensitive mouse insulin ELISA kit (Crystal Chem no. 90090). Triglycerides were determined using Cardiocheck Lipid panel test strips.

qRT-PCR. mRNA was extracted from the livers of chow- and HF-fed mice, and quantitative RT-PCR was conducted as described (48).

Neutralizing antibody titer. The presence of neutralizing antibodies in serum was determined by the "constant virus-decreasing serum" method as described (3).

Glucose tolerance test. Subsequent to a 16-h fast, conscious mice were injected intraperitoneally with d-glucose (2.5 mg/g body wt). Blood was collected from the tail vein prior to glucose injection (time 0) and at 10, 20, 30, 60, 120, and 150 min PI. Blood glucose was determined using a glucometer (Contour, Bayer).

Western blot analyses. Proteins from adipose tissue, liver, and skeletal muscle were used for Western blot analyses by standard procedure (49). For immunoprecipitation of IR, IRS-1, and IRS-2, tissue samples were homogenized in a buffer containing 50 mM HEPES (pH 7.4), 2 mM sodium orthovanadate, 10 mM sodium fluoride, 2 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, and protease inhibitors. Homogenates (250 μg) were then immunoprecipitated with 3 μg of primary antibody. Samples were subjected to SDS-PAGE using 4–20% gradient gel and transferred to PVDF membranes. The membranes were immunoblotted with anti-phospho antibodies. Antibodies for phosphorylated Tyr1322-IR (Millipore, no. 04-300) and total IR (Millipore, no. 05-1104), total IRS-1 (Santa Cruz, no. Sc-559) and p-IRS-1 (Tyr989; Santa Cruz, no. 9117), glucose-6-phosphatase (G-6-Pase; Santa Cruz, no. 9117), glycogen synthase kinase (Ser21; Santa Cruz, no. 16308), total p-Akt (Thr172; Cell Signaling, no. 2651), and p-Akt (Ser473; Cell Signaling, no. 9271), and p-AMPK (Thr172; Cell Signaling, no. 2535), and leptin (Abcam, no. 2095) antibodies, respectively. Followed by secondary antibody conjugated with horseradish peroxidase, signals were detected by enhanced chemiluminescence. The specific bands were quantitated with scanning densitometry using AlphaEaseFC analyzer software, and equal loading was assessed by normalization to GAPDH (Ambion, no. 4300) abundance.

Histochemistry. Glycogen was stained using periodic acid-Schiff (PAS) stain on flash-frozen liver samples of three mice each from Ad36, Ad2, and mock infected HF-fed mice, and one mock-infected chow-fed mouse as a control as described (4). Glycogen staining gives a magenta color to sections; a darker stain indicates more glycogen. Lipid leaves the sample during fixation; thus, a white blank area on the slide indicates lipid droplets (2).

Human Studies: Experiment 3. Association of Natural Infection of Ad36 with Glycemic Control in Humans

Human serum samples from four cohorts were screened post hoc for the presence of Ad36-neutralizing antibodies as described (3) and were analyzed for differences in available measures of glycemic control between the seropositive and seronegative groups. For each of the cohorts, approvals were obtained from Institutional Review Boards. Detailed information about the individual cohorts is presented in supplementary information (supplementary information is found linked to the online version of this article).

Experiment 1: effect of experimental Ad36 infection on glycemic control in chow-fed mice. Four-week-old female C57B6/J mice were received. They were offered rodent chow (Purina Lab Diet 5001). After 1 wk of acclimatization, total body fat was determined by Bruker Minispec mq10-NMR (nuclear magnetic resonance) analyzer. Mice were divided into three groups matched for body weight and body fat and were inoculated intranasally, orally, and intraperitoneally with 107 PFU of Ad36 (n = 3) or Ad2 (a common human adenovirus used as a control for infection; n = 4) or mock infected with tissue culture medium (n = 6). The body weights were measured weekly, and blood samples were obtained from the intraorbital retrobulbar sinus from anesthetized mice fasted for 4 h. The mice were killed 12 wk postinfection (PI). Trunk blood was collected, and serum was separated and used for glucose and insulin determinations. Liver and retroperitoneal fat depots were carefully separated, weighed, and flash-frozen in liquid nitrogen and stored at −80°C until used for qRT-PCR assay or for Western blot or histology studies as described below in Techniques and Assays. Additional details of the assays are included in supplementary information (supplementary information is found linked to the online version of this article).

Experiment 2: effect of experimental Ad36 infection on glycemic control in high-fat-fed mice. Fourteen-week-old male C57B6/J mice who were fed a high-fat (HF, 60% kcal) diet (Research Diets D12492i) starting at 6 wk of age were received. Upon 1 wk acclimatization, baseline body fat was determined by NMR, and mice were divided into three groups (n = 10/group) matched for body fat and body weight. The groups were infected with Ad36 (0.6 × 106 PFU), Ad2 (3 × 106 PFU), or mock infected intranasally, intraperitoneally, and orally and continued on HF diet (60% kcal) for an additional 20 wk. Food disappearance and body weights were measured weekly for 16 wk, and blood samples were obtained from the infraorbital retrobulbar sinus in anesthetized mice. Fasting samples were collected after removing food for 4 h. The mice were killed 20 wk PI in the free-fed state. Trunk blood was collected. Liver and epididymal and retroperitoneal fat depots were carefully separated, weighed, flash-frozen in liquid nitrogen, and stored at −80°C until use for qRT-PCR assay, or for Western blot or histology studies as described in Techniques and Assays.

Statistical analyses. Differences in food intake, body weights, liver, fat pad weights, and glucose and insulin levels were analyzed by Student’s t-test for both animal experiments. Probability levels were set at P ≤ 0.05.

Techniques and Assays

Additional details about the techniques and assays are described in supplementary information.

Viruses. Ad36 and Ad2 were obtained from American Type Culture collection (ATCC cat. nos. VR913 and VR846, respectively). Ad36 was plaque purified and propagated in A549 cells (human lung cancer cell line) as described (13, 14).

Biochemical assays. Glucose was measured using the Raichem glucose Oxidase method (R80038), and insulin was measured with an ultrasensitive mouse insulin ELISA kit (Crystal Chem no. 90090). Triglycerides were determined using Cardiocheck Lipid panel test strips.

qRT-PCR. mRNA was extracted from the livers of chow- and HF-fed mice, and quantitative RT-PCR was conducted as described (48).

Neutralizing antibody titer. The presence of neutralizing antibodies in serum was determined by the “constant virus-decreasing serum” method as described (3).

Glucose tolerance test. Subsequent to a 16-h fast, conscious mice were injected intraperitoneally with d-glucose (2.5 mg/g body wt). Blood was collected from the tail vein prior to glucose injection (time 0) and at 10, 20, 30, 60, 120, and 150 min PI. Blood glucose was determined using a glucometer (Contour, Bayer).

Western blot analyses. Proteins from adipose tissue, liver, and skeletal muscle were used for Western blot analyses by standard procedure (49). For immunoprecipitation of IR, IRS-1, and IRS-2, tissue samples were homogenized in a buffer containing 50 mM HEPES (pH 7.4), 2 mM sodium orthovanadate, 10 mM sodium fluoride, 2 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, and protease inhibitors. Homogenates (250 μg) were then immunoprecipitated with 3 μg of primary antibody. Samples were subjected to SDS-PAGE using 4–20% gradient gel and transferred to PVDF membranes. The membranes were immunoblotted with anti-phospho antibodies. Antibodies for phosphorylated Tyr1322-IR (Millipore, no. 04-300) and total IR (Millipore, no. 05-1104), total IRS-1 (Santa Cruz, no. Sc-559) and p-IRS-1 (Tyr989; Santa Cruz, no. Sc-17200), p-IRS-1 (Ser637, Cell Signaling, no. 2381), IRS-2 (Millipore, no. 60-506), and p-IRS-2 (Ser612) (Santa Cruz, no. Sc-17959-R), respectively.

Protein concentrations were quantitated by bichinchoninic acid assay and loaded onto the 4–20% or polyacrylamide gel in equal amounts. Proteins were then transferred to PVDF membranes. Membranes were blocked in PBS-Tween 20 containing 3% BSA and incubated with polyclonal or monoclonal antibodies that recognize total PKB (protein kinase B; Cell Signaling, no. 4691), p-PKB (Ser473, Cell Signaling, no. 9271), Ras (Cell Signaling, no. 3965), GLUT1 (Abcam, no. 35826), GLUT4 (Abcam, no. 14683), GLUT2 (Santa Cruz, no. 9117), glucose-6-phosphatase (G-6-Pase; Santa Cruz, no. 7291), total glycogen synthase kinase (Santa Cruz, no. 27198), p-glycogen synthase kinase (Ser21, Santa Cruz, no. 16308), total AMPKα (Cell Signaling, no. 2603), p-AMPKα (Ser79, Thr272, Cell Signaling, no. 2535), and leptin (Abcam, no. 2095) antibodies, respectively. Followed by secondary antibody conjugated with horseradish peroxidase, signals were detected by enhanced chemiluminescence. The specific bands were quantitated with scanning densitometry using AlphaEaseFC analyzer software, and equal loading was assessed by normalization to GAPDH (Ambion, no. 4300) abundance.

Histochemistry. Glycogen was stained using periodic acid-Schiff (PAS) stain on flash-frozen liver samples of three mice each from Ad36, Ad2, and mock infected HF-fed mice, and one mock-infected chow-fed mouse as a control as described (4). Glycogen staining gives a magenta color to sections; a darker stain indicates more glycogen. Lipid leaves the sample during fixation; thus, a white blank area on the slide indicates lipid droplets (2).
RESULTS

Experiment 1: Ad36 Improves Glycemic Control in Chow-Fed Mice

In both animal experiments, neutralizing antibodies to the adenoviruses and/or PCR analyses for viral DNA and/or mRNA in various mouse tissues confirmed mock infection or infection by the expected viruses (Suppl. Table S1). In experiment 1, body weights did not differ among the groups during the 12-wk study. Despite similar baseline levels, fasting serum glucose and insulin progressively decreased only in Ad36-infected mice over the duration of the experiment (Fig. 1, A and B). Furthermore, at 12 wk PI, mean retroperitoneal fat pad weight was twofold greater ($P < 0.03$) and the mean liver weight was 10% lower ($P < 0.04$) in Ad36-infected mice than in the mock-infected mice (Table 1). Thus, in chow-fed mice, Ad36 infection, but not Ad2 infection, increased adiposity yet improved systemic glycemic control.

Experiment 2: Ad36 Improves HF Diet-Induced Hyperglycemia Despite Continued HF Diet and Without Requiring Weight Loss

Experiment 2 investigated whether Ad36 would improve HF diet-induced hyperglycemia. Fourteen-week-old mice fed a HF diet for the prior 8 wk developed a diabetic state as evidenced by high fasting serum glucose levels (>200 mg/dl). At that point, mice were either mock infected or infected with Ad36 or Ad2. By 20 wk PI, all three groups had similar cumulative food intake as well as total body weight and fat pad masses (Table 1; Suppl. Fig. S1). The adipogenic effect of Ad36 was probably overwhelmed by adipogenic effects of HF diet (Table 1). Over the 20-wk period PI, glycemic control was assessed in various ways: by determining fasting glucose and insulin, by glucose tolerance test, and by determining glucose levels in free-fed state. Overall, Ad36, but not Ad2, significantly improved glycemic control.
Table 1. Response of chow-fed and HF-fed mice to Ad36

<table>
<thead>
<tr>
<th></th>
<th>Mock Infected</th>
<th>Ad36</th>
<th>Ad2</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>6</td>
<td>3</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Body weight, g, week 0</strong></td>
<td>16.3 ± 0.44</td>
<td>16.9 ± 0.12</td>
<td>16.2 ± 0.22</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Body fat, g, week 0</strong></td>
<td>2.1 ± 0.08</td>
<td>2.3 ± 0.11</td>
<td>2.0 ± 0.05</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Body weight, g, week 12</strong></td>
<td>22.3 ± 0.34</td>
<td>23.8 ± 1.02</td>
<td>22.5 ± 0.72</td>
<td></td>
</tr>
<tr>
<td><strong>Retropertioneal fat, g, week 12</strong></td>
<td>0.18 ± 0.02</td>
<td>0.36 ± 0.08*</td>
<td>0.25 ± 0.06</td>
<td></td>
</tr>
<tr>
<td><strong>Liver, g</strong></td>
<td>1.00 ± 0.04</td>
<td>0.9 ± 0.05*</td>
<td>1.0 ± 0.1</td>
<td></td>
</tr>
</tbody>
</table>

**Baseline and final characteristics of chow-fed mice, means ± SE**

<table>
<thead>
<tr>
<th></th>
<th>Mock Infected</th>
<th>Ad36</th>
<th>Ad2</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight, g, week 0</td>
<td>36.2 ± 0.9</td>
<td>36.1 ± 1.1</td>
<td>37.3 ± 1.0</td>
<td>NS</td>
</tr>
<tr>
<td>Body weight, g, week 20</td>
<td>51.5 ± 0.8</td>
<td>48.3 ± 2.1</td>
<td>50.7 ± 1.2</td>
<td>NS</td>
</tr>
<tr>
<td>Cumulative food Intake, g, measured 16 wk postinfection</td>
<td>186 ± 9.2</td>
<td>186 ± 13.3</td>
<td>184 ± 13.7</td>
<td></td>
</tr>
<tr>
<td>Total body fat, g, week 0</td>
<td>10.5 ± 0.8</td>
<td>10.7 ± 0.7</td>
<td>11.5 ± 1.0</td>
<td>NS</td>
</tr>
<tr>
<td>Body fat, g, week 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epididymal</td>
<td>1.41 ± 0.05</td>
<td>1.36 ± 0.13</td>
<td>1.46 ± 0.18</td>
<td>NS</td>
</tr>
<tr>
<td>Retropertioneal</td>
<td>0.49 ± 0.02</td>
<td>0.52 ± 0.05</td>
<td>0.47 ± 0.02</td>
<td>NS</td>
</tr>
<tr>
<td>Liver, g</td>
<td>2.73 ± 0.1</td>
<td>2.34 ± 0.17*</td>
<td>2.36 ± 0.24</td>
<td></td>
</tr>
<tr>
<td>Serum triglycerides, mg/dl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 0</td>
<td>71.6 ± 1.7</td>
<td>71.2 ± 0.9</td>
<td>71.5 ± 1.2</td>
<td>NS</td>
</tr>
<tr>
<td>Week 8</td>
<td>70.4 ± 2.1</td>
<td>68.3 ± 1.2*</td>
<td>69.3 ± 1.0</td>
<td>*P &lt; 0.05 vs. week 0 of Ad36</td>
</tr>
</tbody>
</table>

qRT-PCR data of expression of genes in livers of mice fed chow or HF diet

| Diet    | FAS | SREBP1c | FoxO1 | AdipoR1 | AdipoR2 | CPT I | LXR | PPARα | apoB | MTP | IL-6 | IL-10 | INFγ | TNFα |
|---------|-----|---------|-------|---------|---------|-------|-----|-------|------|-----|------|-------|------|------|------|
| Chow    | NS  | NS      | ↑*    | ↑*      | ↑*      | NS    | ↑*  | NS    | ↑*   | NS  | NS   | NS    | NS   | NS   | NS   |
| HF      | NS  | ↓ (0.08) | ↑ (0.07) | NS | NS | NS | NS | NS | ↑* | NS | ↓ (0.06) | NS | NS | NS |

Arrows indicate direction of changes induced by Ad36 compared with mock-infected group. HF, high fat; NS, no significant difference. *P < 0.05 or better. To indicate trend, P value is also denoted, if between 0.05 and 0.1.

control compared with the mock-infected group, and the effect lasted for the 20-wk duration of the experiment (Fig. 1).

Specifically, due to the HF diet-induced insulin resistance, mock-infected mice had an expected increase in fasting serum glucose and insulin. Whereas Ad36 significantly attenuated these increases at 4 or 8 wk PI (Fig. 1, C and D, and Suppl. Fig. S2). Blood glucose clearance in response to an intraperitoneal glucose tolerance test (ipGTT) at 12 wk PI, from its peak at 60 min to the end of the assay 150 min post-glucose infusion, was significantly quicker in Ad36-infected mice (Fig. 1E). At 20 wk PI, Ad36-infected mice had lower free-fed serum glucose levels (Fig. 1F). These free-fed serum glucose levels of all Ad36-infected mice were in the lower 50th percentile compared with those of mock-infected mice (Suppl. Fig. S2; χ-test, P = 0.01).

The phenotypic effect of Ad36 on glucose metabolism correlated to the load of infection. Serum glucose levels at the termination of the experiment (20 wk) significantly and negatively correlated with the amount of Ad36 DNA in livers of respective mice from the Ad36 group (r = −0.94, 2-tailed P = 0.001) by the standard curve method and r = −0.91, 2-tailed P = 0.001 by ΔΔCT method of real-time PCR (Suppl. Fig. S3; methods described in SUPPLEMENTARY INFORMATION). The correlation was not significant for the Ad2 group (P = 0.5 or 0.7 for the two methods, respectively). Thus, Ad36 improves glycemic responses in diabetic mice under both fasted and fed conditions in a viral load-dependent manner. Probably due to the semi-quantitative nature of antibody titer, no significant correlation was observed between antibody titers and phenotypic outcomes for Ad36 or Ad2 (Suppl. Fig. S4). Only four of ten mice from the Ad2 group were seropositive at 20 wk PI. Despite a fivefold higher dose of inoculation used for Ad2 vs. Ad36, Ad2 failed to significantly improve hyperglycemia compared with the mock group. Modulation of glycemic control by Ad2 did not reach statistical significance yet showed some trend. A virus would exert a set of characteristic influences on its host. It would be important to identify which difference in the action of the two adenoviruses determines their metabolic effects. This would help in screening other members of human adenovirus group for actions similar to Ad36.

Western blot analyses conducted for mice tissues from experiment 2 showed that, in agreement with our in vitro data (49, 62), Ad36 upregulated the Ras-PI3K pathway as indicated by significantly greater abundance of Ras and phospho-Akt in skeletal muscle, adipose tissue, and liver compared with mock-infected mice (Fig. 2). Probably via this upregulation of distal insulin signaling, Ad36 increased abundance of Glut4 and Glut1 proteins in skeletal muscle and adipose tissue (Fig. 2), indicators of enhanced glucose uptake, whereas Ad36 lowered Glut2 abundance and Glucose-6-phosphatase (G-6-Pase) in the liver (Fig. 2), which may contribute to enhanced glucose uptake, whereas Ad36 lowered Glut2 abundance and Glucose-6-phosphatase (G-6-Pase) in the liver (Fig. 2), indicators of a reduction in hepatic glucose release. Thus, increased Ad36 appears to improve systemic glycemic control by upregulating skeletal muscle and adipose tissue glucose uptake and by reducing hepatic glucose release. Future experiments, including hyperinsulinemic-euglycemic clamp studies and tissue-specific glucose disposal, should further clarify this model.
Insulin induces IRS signaling (proximal insulin signaling) to activate the PI3K pathway (distal insulin signaling), which upregulates glucose uptake. Consistent with previous in vitro findings (49, 62), Ad36 downregulated levels of activated, tyrosine-phosphorylated IR, IRS-1, and IRS-2 and upregulated levels of inactivated, serine-phosphorylated IRS-1 (Fig. 2) yet upregulated glucose disposal. Although the precise reason for the downregulation of IRS-1 action is unknown, it may be due to the effect of Ad36 on tumor necrosis factor-α (TNFα), which functionally inhibits IRS-1 by inducing its serine phosphorylation (20). Adipose tissue from Ad36-infected mice expressed 2.5-fold higher TNFα mRNA levels than did mock-infected mice (Suppl. Fig. S5). Likewise, Ad36 also significantly increased mRNA levels of other inflammatory cytokines such as MCP1 and CD68 (Suppl. Fig. S5), which have also been implicated in downregulation of insulin receptor signaling and insulin resistance (46). Ad36 enhances glucose disposal despite the impaired proximal insulin signaling pathway, probably because the robust upregulation of the distal insulin signaling by Ad36, including the PI3K and Glut4 pathways, compensates for the effect.

Although Ad36 DNA/mRNA was detected in various tissues of the mice, it is unclear whether Ad36 alters metabolism directly in these tissues. For instance, changes in glucose metabolism in the liver and skeletal muscle could be secondary to the effects of adiponectin, a key adipose tissue-expressed adipokine that improves glycemic control (41). Adiponectin exists as higher-, medium-, and lower-molecular-weight (MW) forms, although the higher MW form is most strongly linked to insulin sensitivity (51). PI3K is a strong promoter of adiponectin secretion (7, 44). Via the activation of the PI3K pathway, Ad36 appears to significantly increase levels of total adiponectin and all its molecular weight forms in adipose tissue of HF diet-fed mice (Figs. 2 and 3). Adiponectin acts via adiponectin receptors AdipoR1 and AdipoR2 to activate AMPK (AMP-activated protein kinase) in skeletal muscle and liver to promote glucose uptake in skeletal muscle (64) and to protect liver against steatosis (66). Furthermore, adiponectin upregulates PPARα pathways (25), decreases systemic and hepatic insulin resistance, and attenuates liver inflammation and fibrosis (25). Ad36-infected HF-fed mice showed higher levels of the activated, phosphorylated-AMPK in skeletal muscle and liver compared with mock-infected or Ad2-infected mice (Fig. 2). AMPK activation promotes insulin-independent glucose disposal (68). Therefore, we postulate that Ad36 directly increases adiponectin expression in adipose tissue, which contributes to the systemic improvement in metabolic profile.

Ad36 may alter determinants of hepatic lipid accumulation. As expected, liver sections of HF diet-fed mice displayed less glycogen and more lipid than the liver section of a chow-fed mouse (Fig. 4). Within the HF diet-fed groups, however, Ad36 appeared to protect from the hepatic effects of the HF diet, as evidenced by significantly increased glycogen and lower lipid content in livers compared with mock-infected mice (P < 0.02; Fig. 4).

The metabolic regulation of hepatic lipid storage is complex. Potential determinants of hepatic lipid levels include synthesis (lipogenesis), utilization (fat oxidation), and export of hepatic lipids (26). Due to the reduction in hepatic lipid accumulations by Ad36, we tested the differences in expressions of selected
hepatic genes of chow-fed and HF-fed mice. Although these molecules have overlapping roles in multiple pathways, we considered FAS (fatty acid synthase), SREBP-1c (sterol response element-binding protein-1c), and FOXO1 (forkhead transcription factor) to indicate lipid oxidation (29, 34, 65) and MTP (microsomal triglyceride transfer protein) and apoB (apolipoprotein B) as indicative of lipid export (32, 57). Since hepatic steatosis coupled with inflammation may signal the progression to nonalcoholic steatohepatitis (NASH), markers of inflammation were also determined.

The overall gene expression results are summarized in Table 1. The hepatic gene expressions were determined 12–20 wk PI. Although such a long-period PI and HF diet may mask some changes, gene expressions from the chow-fed and HF-fed mice collectively suggest that Ad36 increases adiponectin receptor expression and reduces lipogenesis, upregulates lipid oxidation, and reduces inflammation in the liver (Table 1). Interestingly, a recent study showed that AMPK activation in the liver downregulates IL-6-mediated inflammatory response (38). This appears to be the case in livers of HF-fed mice of the Ad36 group.

These findings present a new animal model, wherein Ad36 may increase glucose uptake by skeletal muscle and adipose tissue and reduce glucose release and lipid accumulation by the liver, thereby significantly improving systemic glycemic control and HS (Fig. 5).

Experiment 3: Ad36 Is Associated with Better Glycemic Control and Lower HS in Humans

To methodically test the association of Ad36 with adult and pediatric serum samples from four cohorts that covered a wide range of age, race, and BMI were screened retrospectively for Ad36 antibodies. Presence of Ad36 antibodies indicated past natural infection with the virus. Serum neutralization assay, the highly specific and sensitive but labor-intensive gold standard for determining neutralizing antibodies, was used. Until the results of antibody testing were available, the investigators were blinded to the available phenotypic data.

The stability of Ad36 antibodies after natural infection was assumed in subjects. About 13% of individuals from the HERITAGE Family Study (8) scored positive for Ad36 antibodies (Table 2), and such individuals had better insulin sensitivity (3.65 ± 0.23 vs. 3.06 ± 0.09, 10⁻⁴ min/mU/ml, \( P = 0.007 \)) than did Ad36 seronegative individuals. Ad36 infection was associated with better glycemic control as indicated by greater insulin sensitivity in whites (\( P = 0.026 \)) and greater disposition index (\( P = 0.004 \)) in blacks. In the PBRC cohort, 18% subjects were seropositive for Ad36 and had significantly lower fasting glucose and fasting insulin levels and lower insulin resistance as indicated by HOMA-IR (homeostatic model of insulin resistance) index (Table 2).

In the MET cohort, 22% of these healthy, exclusively prepubertal children were Ad36 seropositive and showed significantly lower fasting glucose, fasting insulin, and lower HOMA-IR (Table 2) than did Ad36 seronegative children. Only 7.1% of samples from the Viva La Familia study (9) scored positive for Ad36 antibodies and had better glycemic control as indicated by significantly lower fasting glucose (\( P = 0.04 \)) and greater odds ratio (OR) to have fasting glucose (\( P = 0.05 \)), fasting insulin (\( P = 0.01 \)), and HOMA-IR (\( P = 0.01 \)), below the median of the overall group, compared with that for the Ad36 seronegative group (Table 2). Some indexes of glycemic control varied based on their availability for a cohort. However, remarkably, the association of Ad36 infection with better glycemic control was consistently valid across cohorts of diverse age groups and races of over 1,500 individuals. It is interesting that Ad36 seropositivity-based differences in insulin emerged even in children, whose mean insulin levels were well within the normal range. It is also intriguing that, despite the numerous potential factors that might influence glycemic control in adults, past Ad36 infection was a significant protective factor, independent of age, sex, and adiposity. It is unknown whether the relatively lower prevalence of Ad36 infection observed in Hispanic children contributes to the greater risk of diabetes reported in Hispanic population (11).

Measures assessing intrahepatic lipid (IHL) content were available in the PBRC and MET cohorts. In both cohorts, Ad36 infection was associated with significantly lower IHL (Table 1). These findings agree well with a recent report of protection from nonalcoholic fatty liver disease (NAFLD) in Ad36 seropositive people (60). These findings suggest that Ad36 infection may protect individuals from impaired glucose tolerance (IGT) and HS, two key risk factors associated with type 2 diabetes and serious liver diseases.

Thus, experimental Ad36 infection of mice improved glycemic control and HS, and those humans who were naturally infected with Ad36 mirrored these findings.
DISCUSSION

Some salient features of this study are that 1) despite increased adiposity (experiment 1) or continued HF diet (experiment 2), Ad36 robustly and lastingly improved systemic glycemic control and reduced HS; 2) the improvement in systemic glycemic control was a nontransient and specific response to Ad36 infection; 3) robust upregulation of adiponectin and distal insulin signaling by Ad36 appears to contribute to these metabolic improvements; 4) improvement in glycemic control by Ad36 was despite the downregulation of proximal insulin signaling; 5) natural Ad36 infection in humans mirrors the effects induced by the virus in experimentally infected animals. These aspects are discussed below.

1) Excess adiposity, HF-diet, impaired insulin signaling, and adipose tissue inflammation are important risk factors for several serious conditions including type 2 diabetes, NAFLD and NASH and cardiovascular diseases. Reducing dietary fat intake and obesity is the mainstay of the behavioral component and an adjunct to effective drug treatment of these health conditions. Despite their obvious health benefits, compliance with lifestyle changes to achieve sustained improvements in diet or obesity has proved challenging for the general population. Therefore, drugs that improve diabetes independently of adiposity or dietary fat intake would be extremely attractive and of practical benefit. Also, most of the currently available antidiabetic agents are mimetics, sensitizers, or secretagogues of insulin, that employ the insulin signaling pathway for their action. However, insulin-resistant states such as obesity or diabetes are often associated with impaired proximal insulin signaling (21, 40, 45, 52–55), which may limit the efficacy of such drugs. Thus, there is an urgent need to develop new drugs that improve glycemic control independent of insulin signaling, and independent of dietary fat intake or obesity. The unique capability of Ad36 offers a model to creatively negate the ill effects of excess adiposity or excess dietary fat intake without the need to reduce it.

2) In both animal experiments, the improvement in glycemic control persisted for the entire duration of the study. Ad2 infection did not improve glycemic control indicates, which suggests that the phenotypic changes were not a nonspecific response to an infection but were specific to the proteins of Ad36. The specific role of Ad36 is further highlighted by a strong correlation between the viral DNA load and the improved glycemic control observed.

3) By upregulating adiponectin, its receptors in the liver (AdipoR1 and AdipoR2), and its target molecule (AMPK), Ad36 appears to improve glucose and hepatic metabolism independently of adiposity. In fact, adiponectin accounts for a subtype of “insulin-sensitive obesity”, independent of total fat mass (28). Overexpression of adiponectin increases body fat yet improves glycemic control (27). Likewise, the thiazolidinedione (TZD) class of drugs upregulate adiponectin and improve hyperglycemia and HS (35). But better drugs are needed, as some serious side effects of TZDs have been recently reported (33, 39). To that effect, Ad36 does not cause morbidity or unintended mortality in animals. In addition, Ad36 appears to have distinct advantages over the action of the TZDs, particularly in the presence of a HF diet. Unlike the TZDs, Ad36 does not increase adiposity in HF-fed mice (19).
Moreover, in presence of a HF diet, TZDs improve glycemic control, but they concurrently promote lipid storage in various organs, including the liver (30, 58). This may limit the scope of TZDs, if fat intake is not reduced, which is not a limitation for Ad36.

4) Ad36 enhances glucose disposal despite the impaired proximal insulin signaling, probably because the robust upregulation of the distal insulin signaling by Ad36 compensates for the effect. The downregulation of proximal insulin signaling by Ad36 does not induce insulin resistance, which would have been characterized by elevated fasting insulin with normal or elevated fasting glucose. Instead, Ad36 reduces fasting glucose and insulin. This is probably because less insulin is required to maintain glucose homeostasis due to enhanced glucose disposal by the virus. Thus, the improvement in glucose disposal by Ad36 should be regarded as its “insulin sparing action”. Hence, as observed in vitro (49, 62), the in vivo effect of Ad36 on glucose disposal also appears independent of proximal insulin signaling. The distal insulin signaling pathway recruited by Ad36 may not require insulin action. Such a potential agent may especially benefit advanced-stage type 2 diabetics, who usually require insulin therapy but often respond weakly due to impaired insulin signaling. Similarly, insulin-independent glucose disposal may also be useful for the treatment of type 1 diabetes as an adjunct to insulin treatment.

5) Importantly, we revealed a link between natural Ad36 infections of humans and better glycemic control and lower hepatic lipid, which may have valuable health implications. It is suggested that hepatic lipid, and not visceral fat, is a determinant of metabolic syndrome (18, 36). Moreover, hepatic fat accumulation could lead to NAFLD or further serious consequences. The prevalence of NAFLD is about 70–80% in adults with type 2 diabetes or obesity (5, 42, 56), 3–10%, in all children, and up to 40–70% in obese children (5). NAFLD is associated with greater overall and liver-related mortality (1, 17). In addition to steatosis, inflammation and fibrosis can develop, and NAFLD may progress to NASH, cirrhosis, liver failure, and hepatocellular carcinoma. Although steatosis is potentially reversible, once it progresses to NASH, there is no established treatment, and the few available medications show limited success (22, 50); therefore, the timely prevention and/or treatment of hepatic steatosis is critical. However, even for NAFLD, drug treatment has marginal success (16), and reducing dietary fat intake and obesity are recommended (37), which is challenging. Therefore, agents to lower hepatic steatosis independently of adiposity or dietary fat intake would be extremely attractive and of practical benefit. Ad36 may provide a template to develop such an approach.

The congruence of results from the human and animal studies particularly strengthens the findings. Also, these findings underscore the need to consider Ad36 infection status as a potential confounder in epidemiological studies that investigate parameters related to glucose metabolism. Importantly, the association of Ad36 with better glycemic control in humans strongly supports the human relevance of the antidiabetic attributes of Ad36 proteins.

Although viruses are generally considered causative agents for disease, we report surprising evidence suggesting that an
infection with Ad36 favorably alters host glucose metabolism. The long-term goal of this study is not to recommend Ad36 infection for improving metabolic profile but to use it as a tool and exploit its properties to develop more effective strategies for managing hyperglycemia. Such an approach of harnessing certain properties of viruses for beneficial purposes has been creatively used for several years, including the use of bacteriophage virus (24), the oncolytic ability of a mutant adenovirus (6), or the use of Herpes simplex virus and several other viruses for the treatment of cancers (12). Similarly, Ad36 offers a new model. This model may be used to reveal how the host metabolism could be manipulated without reducing dietary fat or adiposity, a highly desirable attribute for the treatment/prevention of IGT or HS. This information may provide a template to develop novel antidiabetic approaches that are clinically more attractive, hence, potentially more effective.

**GRANTS**

The research was funded in part by 1) the American Diabetes Association (1-09-IN-13) and The Mathile Institute for the Advancement of Human Nutrition grants awarded to N. V. Dhurandhar; 2) The HERITAGE Family Study has been funded by multiple grants from National Institutes of Health (HL-45670, HL-47323, HL-47317, HL-47327, HL-47321) to C. Bouchard, T. Rankinen, and others. C. Bouchard is partially funded by the George A. Bray Chair in Nutrition; 3) National Institute of Child Health and Human Development IR01 HD-41071-01A2, IR01 HD-49046-05, National Institute of Diabetes and Digestive and Kidney Diseases (CNRU) 1P30 DK-072476, and the LSU Health Sciences Center and Tulane University CTRC; 4) the Viva La Familia Study and related work were funded by National Institute of Diabetes and Digestive and Kidney Diseases R01 DK-59264 and USDA/ARS 58-6250-51000-037 to N. B; 5) This work used Genomics core facilities at the Pennington Biomedical Research Center that are supported in part by COBRE (P20-RR021945) and NORC (1P30 DK-072476) grants from the National Institutes of Health.

**Table 2. Association of Ad36 seropositivity with measures of glycemic control**

<table>
<thead>
<tr>
<th>Heritages Family Study: Adult men and women (n = 671)</th>
<th>Black Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad36−</td>
<td>Ad36+</td>
</tr>
<tr>
<td>n = 671</td>
<td>n = 406</td>
</tr>
<tr>
<td>Fasting insulin, pmol/l</td>
<td>56.8 (54.3–59.4)</td>
</tr>
<tr>
<td>Fasting glucose, mg/dl</td>
<td>90.7 (89.8–91.5)</td>
</tr>
<tr>
<td>Insulin sensitivity, 10⁻⁴ min/mU/ml</td>
<td>3.85 (3.63–4.08)</td>
</tr>
<tr>
<td>Disposition index, s × AIRg</td>
<td>2214 (2,075–2,358)</td>
</tr>
<tr>
<td>AIRg, 10 min/mU/ml</td>
<td>627 (389–668)</td>
</tr>
<tr>
<td>Glucose effectiveness, min⁻¹</td>
<td>0.016 (0.015–0.017)</td>
</tr>
</tbody>
</table>

**PBR/C study: adult men and women (n = 206) | black/white/other, 74/118/14; mean (95% CI) adjusted for age, sex, and BMI**

| Fasting insulin, pmol/l | 96.9 (92.6–101.3) | 92.3 (87.1–97.6) | 0.004 |
| Fasting glucose, mg/dl | 74.5 (71.6–77.4) | 68.7 (62.9–74.6) | 0.026 |
| Fasting insulin, µU/ml | 11.6 (9.6, 14.0) | 9.4 (7.1, 12.4) | 0.04 |
| HOMA IR | 2.7 (2.2, 3.3) | 2.1 (1.6, 2.8) | 0.01 |
| Liver density* (HU) | 10.7 (8.5, 13.4) | 13.0 (9.9, 17.2) | 0.02 |
| Glucose effectiveness, min⁻¹ | 0.005 (0.002–0.006) | 0.003 (0.004–0.008) | 0.04 |

*Normarlized to spleen density. Higher HU value equates to lower lipid content.

**MET study: prepubertal boys and girls (n = 45); black/white/other, 10/32/3; mean (95% CI) adjusted for age, sex, and BMI**

| Fasting insulin, pmol/l | 92.2 (91.3–93.0) | 89.1 (85.8–92.4) | 0.04 |
| Fasting insulin, µU/ml | 15.9 (15.2–16.6) | 16.6 (13.9–19.8) | NS |
| HOMA IR | 3.58 (3.42–3.76) | 3.65 (3.03–4.40) | NS |
| Glucose effectiveness, min⁻¹ | 92.2 (91.3–93.0) | 89.1 (85.8–92.4) | 0.04 |

**OR for Ad36+ to be below the median of the overall group**

<table>
<thead>
<tr>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting glucose</td>
<td>2.5</td>
<td>1.1–5.7</td>
</tr>
<tr>
<td>Fasting insulin</td>
<td>1.8</td>
<td>0.9–3.4</td>
</tr>
<tr>
<td>HOMA IR</td>
<td>2.4</td>
<td>1.1–5.3</td>
</tr>
</tbody>
</table>

*Arithmetic mean for glucose; geometric mean for insulin, HOMA IR, and intrahepatic lipid.
REFERENCES


18. E788 AD36 ATTENUATES DIET-INDUCED HYPERGLYCEMIA


33. Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) 18: 1510–1515, 2010.


